Liborio Torregrossa
Overview
Explore the profile of Liborio Torregrossa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
1636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Capezzone M, Torregrossa L, Poma A, Cartocci A, Petrone L, Sparano C, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075565
Thyroid cancer (TC) is the most common endocrine malignancy, and its incidence continues to rise worldwide [...].
2.
Prete A, Torregrossa L, Gambale C, Ciampi R, Ramone T, Romei C, et al.
Thyroid
. 2025 Feb;
PMID: 39930944
The international medullary thyroid carcinoma (MTC) grading system (IMTCGS) has been proposed as an independent tool to predict disease-specific survival (DSS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS)....
3.
Dinoi E, Prete A, Sardella C, Pierotti L, Della Valentina S, Dal Lago A, et al.
Front Endocrinol (Lausanne)
. 2024 Nov;
15:1414896.
PMID: 39493781
Background: Brown tumors are rare bone manifestations of primary hyperparathyroidism (PHPT) that may occur at different sites either as single or multiple lesions and they can easily be mistaken for...
4.
Matrone A, Faranda A, Torregrossa L, Gambale C, Minaldi E, Prete A, et al.
Curr Oncol
. 2024 Sep;
31(9):5528-5536.
PMID: 39330037
Background: Differentiated thyroid carcinoma (DTC), mainly papillary (PTC), at low risk of recurrence is currently managed with active surveillance strategies or less aggressive surgeries. However, total thyroidectomy with I treatment...
5.
Ramone T, Ghirri A, Prete A, Matrone A, Ciampi R, Piaggi P, et al.
J Clin Endocrinol Metab
. 2024 Aug;
110(3):685-692.
PMID: 39180363
Context: The active surveillance (AS) program for papillary thyroid carcinoma (≤1 cm) at low risk (mPTC) showed a low percentage of progression. Objective: The aim of this study was to...
6.
Casalini R, Romei C, Ciampi R, Ramone T, Prete A, Gambale C, et al.
Endocrine
. 2024 Aug;
87(1):243-251.
PMID: 39179735
Purpose: Aims of this study were to investigate the prevalence of TP53 and TERT mutations in Medullary Thyroid carcinoma (MTC) and their role in inducing aggressiveness in positive cases. Methods:...
7.
Barbaro D, Forleo R, Profilo M, Lapi P, Giani C, Torregrossa L, et al.
Front Endocrinol (Lausanne)
. 2024 Jul;
15:1389294.
PMID: 39045273
Background: Tyrosine kinase inhibitors (TKIs) and immunotherapy have been proposed for advanced metastatic anaplastic thyroid cancer (ATC). We report a case of V600E-mutated ATC in which lenvatinib (L) plus pembrolizumab...
8.
Pardi E, Poma A, Torregrossa L, Pierotti L, Borsari S, Della Valentina S, et al.
J Clin Endocrinol Metab
. 2024 Jun;
110(1):48-58.
PMID: 38940486
Context: Atypical parathyroid tumor (APT) represents a neoplasm characterized by histological features typical of parathyroid carcinoma (PC) but lacking local infiltration and/or distant metastasis, leading to uncertainty regarding its malignant...
9.
Capezzone M, Rossi M, Macerola E, Cantara S, Pepe F, Morabito E, et al.
Case Rep Endocrinol
. 2024 Mar;
2024:6621510.
PMID: 38532782
Papillary thyroid cancer (PTC) is a common endocrine malignancy, and its incidence is reported to be constantly increasing. BRAF mutation is detected in approximately 44% of PTCs, and the most...
10.
Campenni A, Torregrossa L, Ruggeri R, Petranovic Ovcaricek P, Siracusa M, Giovanella L
Endocrine
. 2024 Feb;
85(1):142-145.
PMID: 38340243
The term noninvasive tumor with a follicular growth pattern and nuclear features of papillary thyroid cancer (NIFTP) is used to describe a tumor currently considered as a pre-malignant lesion for...